2Eyes Vision Stock

Technological and clinical validation of the SimVis technology to treat presbyopia with multifocal contact lenses

Sign up today and learn more about 2Eyes Vision Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About 2Eyes Vision Stock

Developer of creation and marketing of cutting-edge ophthalmic technologies designed to create tools for the ophthalmic sector, with a particular focus on presbyopia, an eye ailment that affects everyone over the age of 45 and everyone who requires cataract surgery. The company commercializes a visual simulator of presbyopic corrections that allows presbyopic patients seeking refractive or cataract surgery for spectacle independence, to experience the real world through different commercially available solutions before undergoing surgery, enabling opticians to recommend patients a noninvasive, personalized assessment before treatment.

Funding History

June 2017$50K
October 2017$1.5M
November 2020$1.3M
April 2021$100K
March 2022$738K
July 2022$556K
October 2022$112K
December 2022$76K
December 2022$199K
April 2023$538K


Co-Founder, President and CEO

Carlos Dorronsoro

Sales Director

Teresa Filhó


Enrique Gambra


Susana Marcos

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: